Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
On January 9, 2026, Ping
An Biomedical Co., Ltd. (the “Company”) issued two press releases. The first press announces entering into a series of share
purchase agreements with several investors, and is filed as exhibit 99.1 to this Form 6-K. The second press announces the Company’s
Strategic Investment in Future Biotechnology Group and is filed as exhibit 99.2 to this Form 6-K.
The foregoing descriptions
of the press releases do not purport to be complete and are qualified in their entirety by reference to the respective press releases,
which are filed as Exhibit 99.1 and Exhibit 99.2.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Exhibit 99.1
Ping An Biomedical Co., Ltd. Receives Strategic
Investment from
Leading Industry Capital, Accelerating Growth in
Biopharmaceutical Innovation
Hong Kong, January 9, 2026 — Ping An Biomedical
Co., Ltd. (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) today announced that it has entered into a series of share
purchase agreements with several investors.
Ping
An Biomedical Co., Ltd. has entered into a series of share purchase agreements from several investors: Yao Jinbo, Chairman and CEO of
58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd ; and Li Daxue, Chairman and CEO of Magcloud Group
Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor. This round of investment further strengthens the
company’s long-term development in biopharmaceutical R&D, medical technology, and innovation .
Yao Jinbo of 58 Group: An Entrepreneur with
a Proven Track Record of Capturing Megatrends
As one of China’s most representative internet
entrepreneurs, Yao Jinbo is the Chairman and CEO of 58.com and a seasoned investor. His investment portfolio spans internet platforms,
lifestyle services, technological innovation, and emerging industries, and he is well known for his forward-looking industrial judgment
and long-term value investing philosophy.
Across multiple economic cycles, Yao has successfully
invested in sectors with structural growth opportunities. His decision to invest in Ping An Bio marks another important strategic move
in the biotechnology, healthcare, and pharmaceutical space. Industry observers view this not merely as a financial investment, but as
a strong endorsement of Ping An Bio’s technology commercialization capabilities, business model, and long-term growth potential.
According to public information, this is Yao Jinbo’s second major investment in the pharmaceutical sector within the past year,
following his RMB 662 million investment in Yiming Pharmaceutical Holdings.
Wang Donghui of Amiba Capital: From Kingsoft
CFO to Industrial Investor
Wang Donghui is a leading figure in China’s
venture capital sector and the founding managing partner of Amiba Capital. He previously served as Chief Financial Officer and Senior
Vice President of Kingsoft Corporation, working closely for many years with Lei Jun, founder of Xiaomi, and participating in Kingsoft’s
Hong Kong IPO. Unlike purely financial investors, Wang places greater emphasis on a company’s underlying R&D capabilities and
long-term value vision. He has made precise investments in multiple unicorn companies such as Meituan, Didi, Mogujie, and Jushuitan. As
of 2025, Amiba Capital manages RMB 5 billion in RMB-denominated funds. Ping An Bio stands out in terms of its biopharmaceutical R&D
pathways, technology implementation capabilities, and long-term technological moat, demonstrating rare potential for scalable growth.
Li Daxue of Magcloud Group: Former JD.com Vice
President with a Strong Industry-Level Strategic Perspective
Li Daxue, former Vice President of JD.com and
its Lifetime Honorary Advisor, brings deep expertise in technology R&D, platform-based operations, industrial integration, and large-scale
enterprise management. His participation in Ping An Bio’s investor lineup signals strong capital market recognition of the company’s
future transition from technological innovation to industrialization, scalability, and standardization.
In the biopharmaceutical sector, it is rare for
a company to receive simultaneous recognition from both “technology capital” and “industrial capital.” This further
highlights Ping An Bio’s unique position within the industry. Consensus among multiple top-tier investors is propelling the company
toward a broader global stage.
Management Commentary
Liu Pijun, Chairman of the Board and Chief Executive
Officer of Ping An Biomedical Co., Ltd, stated:
“We warmly welcome Mr. Li Daxue, Mr. Wang
Donghui, and Mr. Yao Jinbo as strategic investors in the company. Each of them holds benchmark-level influence in technology innovation,
capital operations, and internet platform ecosystems. Their participation will provide comprehensive empowerment to the company across
technology strategy, capital planning, industrial resources, and ecosystem development.”
He further added:
“The company will continue to deepen its
intelligent AI systems while accelerating innovation and commercialization in healthcare and biopharmaceutical technologies. Leveraging
the international capital markets, we will continuously enhance our technological capabilities and global market influence, striving to
become a technology-driven, diversified, and global leader in industrial upgrading.”
About Ping An Biomedical Co., Ltd
Ping An Biomedical Co., Ltd. is a one-stop SCM
service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare
and biomedical technology.
Safe Harbor and Informational Statement
This announcement contains “forward-looking”
statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These
statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of
the Company set forth herein and those preceded by or that include the words “believe,” “expect,” “anticipate,”
“future,” “will,” “intend,” “plan,” “estimate” or similar expressions, are “forward-looking
statements”. Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee
that such expectations are, or will be, correct. These forward looking statements involve a number of risks and uncertainties, which could
cause the Company’s future results to differ materially from those anticipated. These forward-looking statements can change as a result
of many possible events or factors not all of which are known to the Company, which may include, without limitation, our ability to timely
and accurately respond to changes in fashion trends and consumer preferences; management of customer concentration risk; reliance on third
parties for supplies of raw materials, manufacturing services and transport infrastructure; changes in government policy in China; China’s
overall economic conditions and local market economic conditions; our ability to expand through strategic acquisitions and establishment
of new locations; compliance with government regulations; legislation or regulatory environments; geopolitical events, and other events
and/or risks outlined in Ping An Biomedical Co., Ltd’s filings with the U.S. Securities and Exchange Commission. All information
provided in this press release is as of the date of the issuance, and Ping An Biomedical Co., Ltd does not undertake any obligation to
update any forward-looking statement, except as required under applicable law.
For more information, please contact:
Ping An Biomedical Co., Ltd.
Email: corpsec@pingan365.vip
Celestia Investor Relations
Email: investors@celestiair.com
